scholarly journals A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer

2017 ◽  
Vol 10 (6) ◽  
pp. 988-997 ◽  
Author(s):  
Gen Wang ◽  
Xiaosong Chen ◽  
Yue Liang ◽  
Wei Wang ◽  
Kunwei Shen
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Remission Rate ◽  
Neoadjuvant Treatment ◽  
Complete Remission Rate ◽  
Pathological Complete Remission ◽  
Rna Signature

scholarly journals Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e108405 ◽  
Author(s):  
Xiao-song Chen ◽  
Ying Yuan ◽  
David H. Garfield ◽  
Jia-yi Wu ◽  
Ou Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Remission Rate ◽  
Meta Analysis ◽  
Neoadjuvant Treatment ◽  
Complete Remission Rate ◽  
Pathological Complete Remission

scholarly journals The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

2019 ◽  
Vol 9 ◽  
Author(s):  
Elisabet Cuyàs ◽  
Maria Buxó ◽  
Maria José Ferri Iglesias ◽  
Sara Verdura ◽  
Sonia Pernas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Cancer Patients ◽  
Remission Rate ◽  
Complete Remission Rate ◽  
Breast Cancer Patients ◽  
Pathological Complete Remission

Paclitaxel, carboplatin and trastuzumab (TCH) achieves high pathological complete remission rate after in vivo response directed 2–4 cycles of doxorubicin and cyclophosphamide (AC) in breast cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10583-10583
Author(s):  
R. S. Mehta ◽  
T. Schubbert ◽  
K. Kong
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Remission Rate ◽  
Maximal Response ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Topoisomerase Ii Alpha ◽  
Gm Csf ◽  
Pathological Complete Remission

10583 Background: A pathological complete remission (pCR) predicts improved survival in breast cancer (BC). Treatment with AC followed by concurrent TCH improved pCR rates to 87.5% in Her2 positive 8-patient pilot study (SABCS 2004, abs #1110), confirmed by a subsequent phase II study. We hypothesized that response adjusted AC (2–4 cycles), TCH (3–4 cycles) sequence targets topoisomerase II alpha amplified and deleted clone, respectively (SABCS 2005, abs # 5056). We report here the combined analysis of the Her2 positive (fluorescence in situ hybridization + or immunohistochemistry 3+) subset of these studies. Material and Methods: Thirty-one patients with stage IIB-IV BC were accrued. Twenty-eight of 31 patients received AC in a dose dense manner with GM-CSF support. Patients received carboplatin calculated at AUC of 2 and paclitaxel at 80 mg/m2 for 3 weeks followed by 1 week of rest (1 cycle) for a maximum of 4 cycles. Concurrent trastuzumab 4 mg/kg loading dose, then 2 mg/kg/wk was administered for 12–16 weeks. Results: Twenty-nine of 31(94%, CI, 0.79–1) patients showed a clinical complete or partial response (cCR, or cPR). Nineteen of 27 patients (70%, CI, 0.50–0.86) achieved a pCR at surgery; two additional patients had ≤3 mm residual invasive cancer; and lymph node negativity rate was 73%. Of the 3 additional patients with cCR, 1died (underlying cirrhosis), 1 refused surgery, and 1 awaits surgery. A fourth patient with cPR awaits surgery. Ninety percent of the patients (28/31, CI, 0.74–0.98) are alive, and 77% (24/31, CI, 0.59–0. 90) are progression free at median follow up of 19 months (range 6–35 months). Median ejection fraction by echocardiogram was 60% (range 50–74); no patient had clinical cardiac dysfunction. One patient each on GM-CSF and peg-GCSF developed neutropenic fever. Conclusion: Short course of TCH following response adjusted 2–4 cycles of AC will have an improved therapeutic ratio with minimum cardiac toxicity and maximal response. [Table: see text] [Table: see text]

scholarly journals Transcriptome sequencing uncovers a three–long noncoding RNA signature in predicting breast cancer survival

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Wenna Guo ◽  
Qiang Wang ◽  
Yueping Zhan ◽  
Xijia Chen ◽  
Qi Yu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Long Noncoding Rna ◽  
Transcriptome Sequencing ◽  
Noncoding Rna ◽  
Cancer Survival ◽  
Breast Cancer Survival ◽  
Rna Signature

scholarly journals Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen

2018 ◽  
Vol 21 (3) ◽  
pp. 277 ◽  
Author(s):  
Gen Wang ◽  
Xiaosong Chen ◽  
Yue Liang ◽  
Wei Wang ◽  
Yan Fang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Disease Outcome ◽  
Breast Cancer Patients ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer ◽  
Rna Signature

Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression

2007 ◽  
Vol 61 (6) ◽  
pp. 965-971 ◽  
Author(s):  
Andrea Rocca ◽  
Giuseppe Viale ◽  
Richard D. Gelber ◽  
Luca Bottiglieri ◽  
Shari Gelber ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Remission Rate ◽  
Complete Remission Rate ◽  
Primary Chemotherapy ◽  
Pathologic Complete Remission

Long noncoding RNA signature in predicting metastasis following tamoxifen treatment for ER-positive breast cancer

2018 ◽  
Vol 19 (10) ◽  
pp. 825-835 ◽  
Author(s):  
Rong Liu ◽  
Rong Hu ◽  
Wei Zhang ◽  
Hong-Hao Zhou
Keyword(s):  
Breast Cancer ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Tamoxifen Treatment ◽  
Er Positive ◽  
Positive Breast Cancer ◽  
Rna Signature
Sign in / Sign up

Export Citation Format

Share Document